Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/09/2023* -- Results Q4 2022 -- 0.29 --
11/09/2022 -- Results Q3 2022 0.54 2.24 -75.83%
07/27/2022 -- Results Q2 2022 0.62 0.44 41.45%
04/27/2022 -- Results Q1 2022 0.44 0.48 -8.35%
02/09/2022 -- Results Q4 2021 -- -0.01 --
10/27/2021 -- Results Q3 2021 -- -- --
07/28/2021 -- Results Q2 2021 -- -- --
04/28/2021 -- Results Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/09/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/09/2022
Beat/Miss Upgrade
Return Since -2.09%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
URL https://www.inva.com
Investor Relations URL https://investor.inva.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Feb. 09, 2023 (est.)
Last Earnings Release Nov. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Sep. 08, 2015

Dividends

Dividend Per Share (TTM) 0.00
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date Sep. 08, 2015
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
1.52%
32.62%
22.97%
-18.85%
-12.50%
39.23%
-23.19%
-4.53%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
6.28%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
49.38%
-3.19%
31.92%
-1.96%
-30.89%
28.47%
-14.43%
2.37%
6.26%
-7.02%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-10.42%
-13.02%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-85.21%
27.00%
As of January 31, 2023.

Profile

Edit
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
URL https://www.inva.com
Investor Relations URL https://investor.inva.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Feb. 09, 2023 (est.)
Last Earnings Release Nov. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Sep. 08, 2015

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PHSRX 54.04M USD 3.38%
HRSGX 26.32M USD 2.92%
JMCRX 543512.0 USD 2.51%
SMLVX 738025.0 USD 2.07%
SIXS 1.341M USD 2.01%
LYFCX 789480.0 USD 2.00%
AFDVX 2.674M USD 0.85%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter INVA Tweets